Oxford vaccine produces "strong immune response" in older adults

Henrietta Strickland
November 22, 2020

This, the biotech said, is based on its experience with other vaccines and data from preclinical studies with macaques.

Phase three trials of the vaccine are ongoing, with early efficacy readings possible in the coming weeks.

"Our vaccine, therefore, costs about the same as a flu shot, which is between Dollars 10 and USD 50", he was quoted as saying.

Canada has signed a deal with Pfizer for 20 million doses of its vaccine and 56 million doses from Moderna. "We want to deliver to Europe and are in constructive talks". There are now no licensed mRNA vaccines.

As per a press release on the early results, the vaccine was tested in 560 adults who received two doses of the vaccine or a placebo vaccine. This corresponds to an efficacy of 94.5%. Moderna's appears equally effective.

On the one hand, we work with classic products, which use a "dead" virus: they are "inactive" vaccines, such as those of Chinese pharmaceutical companies Sinovac and Sinopharm. And why do they need to be kept so cold?

"Initial results [are] expected in 4 to 6 months".

But experts have cautioned against using data exclusively from emergency use programme, without comparable results from a clinical trial-standard control group, to determine a vaccine's effectiveness.

AstraZeneca and Oxford University's potential Covid-19 vaccine produced a strong immune response in older adults, data published on Thursday showed, with researchers expecting to release late-stage trial results by Christmas.

It's unclear which vaccine Liu referred to, and Sinopharm was not immediately available to comment.

While high-risk groups will be the first vaccinated, the United States government hopes that there will be enough vaccines by April 2021 to offer it to the broader population and provide high coverage by the summer.

It further emerged that the vaccine also proved useful for the patients who were shifted on the ventilator as 60 percent of them recovered after its dose.

"I think the reason we are so delighted is that the immune responses look exactly the same, even in those over 70 years of age".

This is significantly lower than the standard 2-8 degrees Celsius storage requirement. This is the last stage before seeking regulatory approval, and includes tracking the effectiveness of the vaccine in preventing coronavirus.

Other reports by Click Lancashire

Discuss This Article